Pharvaris (PHVS) Competitors

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Pharvaris (NASDAQ:PHVS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, community ranking, media sentiment and dividends.

Do insiders and institutionals believe in ACAD or PHVS?

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 28.3% of ACADIA Pharmaceuticals shares are owned by company insiders. Comparatively, 11.8% of Pharvaris shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Does the MarketBeat Community believe in ACAD or PHVS?

ACADIA Pharmaceuticals received 862 more outperform votes than Pharvaris when rated by MarketBeat users. Likewise, 73.07% of users gave ACADIA Pharmaceuticals an outperform vote while only 66.67% of users gave Pharvaris an outperform vote.

Company	Underperform	Outperform
ACADIA Pharmaceuticals	Outperform Votes 898 73.07%	Underperform Votes 331 26.93%
Pharvaris	Outperform Votes 36 66.67%	Underperform Votes 18 33.33%

Do analysts rate ACAD or PHVS?

ACADIA Pharmaceuticals currently has a consensus target price of $23.93, indicating a potential upside of 64.26%. Pharvaris has a consensus target price of $40.50, indicating a potential upside of 195.19%. Given Pharvaris' stronger consensus rating and higher possible upside, analysts plainly believe Pharvaris is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	8 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50
Pharvaris	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more volatility & risk, ACAD or PHVS?

ACADIA Pharmaceuticals has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, Pharvaris has a beta of -2.84, suggesting that its share price is 384% less volatile than the S&P 500.

Which has higher valuation & earnings, ACAD or PHVS?

ACADIA Pharmaceuticals has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$957.80M	2.54	-$61.29M	$1.36	10.71
Pharvaris	N/A	N/A	-$109.18M	-$2.68	-5.12

Is ACAD or PHVS more profitable?

ACADIA Pharmaceuticals has a net margin of 13.83% compared to Pharvaris' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 25.83% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	13.83%	25.83%	14.71%
Pharvaris	N/A	-38.52%	-36.69%

Does the media favor ACAD or PHVS?

In the previous week, ACADIA Pharmaceuticals had 9 more articles in the media than Pharvaris. MarketBeat recorded 21 mentions for ACADIA Pharmaceuticals and 12 mentions for Pharvaris. ACADIA Pharmaceuticals' average media sentiment score of 1.06 beat Pharvaris' score of 0.33 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	10 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Pharvaris	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

ACADIA Pharmaceuticals beats Pharvaris on 15 of the 17 factors compared between the two stocks.